ArticleCell reports. Medicine2021
Highly specific monoclonal antibodies and epitope identification against SARS-CoV-2 nucleocapsid protein for antigen detection tests.
Article in Cell reports. Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 54 citations in OpenAlex.
- Monoclonal antibody development against the Hepatitis C virus core protein enables rapid antigen detection.Scientific reports · 2026Article
- A bireporter recombinant SARS-CoV-2 Omicron BA.5 forbioRxiv : the preprint server for biology · 2026Article
- Enhanced Detection of SARS-CoV-2 Using Platinum-Decorated Poly(2-vinylpyridine) Nanoparticle-Based Lateral Flow Immunoassay.Biomedicines · 2025Article
- Advancements and Applications of Lateral Flow Assays (LFAs): A Comprehensive Review.Sensors (Basel, Switzerland) · 2025Review
- Development of monoclonal antibodies against SARS-CoV-2 nucleocapsid protein for COVID-19 antigen detection.Tropical medicine and health · 2025Article
- Unleashing Monoclonal Antibodies: Targeting Covid-19's Nucleocapsid Protein and Spike Antigens.Archives of Razi Institute · 2025Article
- A modeling study to define guidelines for antigen screening in schools and workplaces to mitigate COVID-19 outbreaks.Communications medicine · 2025Article
- Compact Digital Immunoassay Platform Integrating ELISA with a Lateral Flow Strip.Biomedicines · 2024Article
- Optical lateral flow assays in early diagnosis of SARS-CoV-2 infection.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024Review
- A sensitive gold nanoflower-based lateral flow assay coupled with gold staining technique for the detection of SARS-CoV-2 antigen.Mikrochimica acta · 2024Article
- Optical biosensors for diagnosis of COVID-19: nanomaterial-enabled particle strategies for post pandemic era.Mikrochimica acta · 2024Review
- Epitopes recognition of SARS-CoV-2 nucleocapsid RNA binding domain by human monoclonal antibodies.iScience · 2024Article
- The evaluation results of proposed antigen rapid diagnostic tests for COVID-19: some possible factors might influence.Infection · 2023Article
- Biopanning of specific peptide for SARS-CoV-2 nucleocapsid protein and enzyme-linked immunosorbent assay-based antigen assay.Analytica chimica acta · 2023Article
- Diagnostics and analysis of SARS-CoV-2: current status, recent advances, challenges and perspectives.Chemical science · 2023Review
- Earliest histopathological changes in COVID-19 pneumonia with comprehensive gene expression analyses: A case series study.Histology and histopathology · 2023Article
- Recent Advances in Molecular and Immunological Diagnostic Platform for Virus Detection: A Review.Biosensors · 2023Review
- Diagnostic performance of a novel antigen-capture ELISA for the detection of SARS-CoV-2.Analytical biochemistry · 2023Article
- State of the art in epitope mapping and opportunities in COVID-19.Future science OA · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ongoing coronavirus disease 2019 (COVID-19) pandemic is a major global public health concern. Although rapid point-of-care testing for detecting viral antigen is important for management of the outbreak, the current antigen tests are less sensitive than nucleic acid testing. In our current study, we produce monoclonal antibodies (mAbs) that exclusively react with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and exhibit no cross-reactivity with other human coronaviruses, including SARS-CoV. Molecular modeling suggests that the mAbs bind to epitopes present on the exterior surface of the nucleocapsid, making them suitable for detecting SARS-CoV-2 in clinical samples. We further select the optimal pair of anti-SARS-CoV-2 nucleocapsid protein (NP) mAbs using ELISA and then use this mAb pair to develop immunochromatographic assay augmented with silver amplification technology. Our mAbs recognize the variants of concern (501Y.V1-V3) that are currently in circulation. Because of their high performance, the mAbs of this study can serve as good candidates for developing antigen detection kits for COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.